Near fatal 5-FU gut toxicity post surgery – remarkable effect of high-dose sucralfate

References

• Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol. 1998;16(11):3537–41.
   PubMedGoogle Scholar
• National Cancer Institute. Common toxicity criteria version 2.0. World Health Organization,June1, 1999.
   Google Scholar
• van Kuilenburg AB. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. Cancer Invest. 2006;24(2):215–7.
   PubMed Web of Science ®Google Scholar
• Boisdron-Celle M, Morel A, Gamelin E. Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine. Ann Biol Clin (Paris). 2010;68(1):27–32.
   PubMed Web of Science ®Google Scholar
• Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. 2007;43(6):1011–6.
   PubMed Web of Science ®Google Scholar
• Milano G, Etienne MC. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics. 1994;4(6):301–6.
   PubMedGoogle Scholar
• Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer. 1999;79(3–4):627–30.
   PubMed Web of Science ®Google Scholar
• Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996;98(3):610–5.
   PubMed Web of Science ®Google Scholar
• Van Kuilenburg AB, Vreken P, Beex LV, Meinsma R, Van Lenthe H, De Abreu RA, et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Adv Exp Med Biol. 1998;431:293–8.
   PubMed Web of Science ®Google Scholar
• Kouwaki M, Hamajima N, Sumi S, Nonaka M, Sasaki M, Dobashi K, et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res. 1998;4(12):2999–3004.
   PubMed Web of Science ®Google Scholar
• Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47(8):2203–6.
   PubMed Web of Science ®Google Scholar
• Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet. 1999;104(1):1–9.
   PubMed Web of Science ®Google Scholar
• Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol. 1989;7(10):1419–26.
   PubMed Web of Science ®Google Scholar
• Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20(6):1491–8.
   PubMed Web of Science ®Google Scholar
• Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103(6):1165–71.
   PubMed Web of Science ®Google Scholar
• van Kuilenburg AB, Baars JW, Meinsma R, van Gennip AH. Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann Oncol. 2003;14(2):341–2.
   PubMed Web of Science ®Google Scholar
• Steiner M, Seule M, Steiner B, Bauer I, Freund M, Köhne CH, et al. 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case. J Clin Pathol. 2005;58(5):553–5.
   PubMed Web of Science ®Google Scholar
• Mounier-Boutoille H, Boisdron-Celle M, Cauchin E, Galmiche JP, Morel A, Gamelin E, et al. Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation. Br J Clin Pharmacol. 2010;70(2):280–3.
   PubMed Web of Science ®Google Scholar
• Chazal M, Etienne MC, Renée N, Bourgeon A, Richelme H, Milano G. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res. 1996;2(3):507–10.
   PubMed Web of Science ®Google Scholar
• Wettergren Y, Carlsson G, Odin E, Gustavsson B. Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. Cancer. 2012;118(11):2935–43.
   PubMed Web of Science ®Google Scholar
• Bocci G, Barbara C, Vannozzi F, Di Paolo A, Melosi A, Barsanti G, et al. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther. 2006;80(4):384–95.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit. 2006;28(5):678–85.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg. 1999;384(6):576–87.
   PubMed Web of Science ®Google Scholar
• Chua TC, Saxena A, Schellekens JF, Liauw W, Yan TD, Fransi S, et al. Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg. 2010;251(1):101–6.
   PubMed Web of Science ®Google Scholar
• Cao CQ, Yan TD, Liauw W, Morris DL. Comparison of optimally resected hepatectomy and peritonectomy patients with colorectal cancer metastasis. J Surg Oncol. 2009;100(7):529–33.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol. 2001;27(3):239–43.
   PubMed Web of Science ®Google Scholar
• Valls A, Pestchen I, Prats C, Pera J, Aragón G, Vidarte M, et al. Multicenter double-blind clinical trial comparing sucralfate vs placebo in the prevention of diarrhea secondary to pelvic irradiation. Med Clin (Barc). 1999;113(18):681–4.
   PubMed Web of Science ®Google Scholar
• O'Brien PC, Franklin CI, Dear KB, Hamilton CC, Poulsen M, Joseph DJ, et al. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. Radiother Oncol. 1997;45(2):117–23.
   PubMed Web of Science ®Google Scholar
• McGinnis WL, Loprinzi CL, Buskirk SJ, Sloan JA, Drummond RG, Frank AR, et al. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis. J Clin Oncol. 1997;15(3):1239–43.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC, et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol. 1997;15(3):1235–8.
   PubMed Web of Science ®Google Scholar
• Kochhar R, Mehta SK, Aggarwal R, Dhar A, Patel F. Sucralfate enema in ulcerative rectosigmoid lesions. Dis Colon Rectum. 1990;33(1):49–51.
   PubMed Web of Science ®Google Scholar
• Jewell LD, Fields AL, Murray CJ, Thomson AB. Erosive gastroduodenitis with marked epithelial atypia after hepatic arterial infusion chemotherapy. Am J Gastroenterol. 1985;80(6):421–4.
   PubMed Web of Science ®Google Scholar
• Blum AL, Bethge H, Bode JC, Domschke W, Feurle G, Hackenberg K, et al. Sucralfate in the treatment and prevention of gastric ulcer: multicentre double blind placebo controlled study. Gut. 1990;31(7):825–30.
   PubMed Web of Science ®Google Scholar
• AHFS Consumer Medication Information 2013 - Sucralfate. http://www.nlm.nih.gov/medlineplus/druginfo/meds/a681049.html.
   Google Scholar
• Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. Dihydropyrimidine Dehydrogenase Deficiency (DPD) in Gi malignancies: experience of 4-years. Pak J Med Sci. 2007;23(6):832–9.
   PubMed Web of Science ®Google Scholar
• Bamat MK. Clinical experience with uridine triacetate for 5-FU overexposure: an update. Chicago, ASCO Annual Meeting Abstracts. [J Clin Oncol. 2013;31(Suppl) (abstr e20592)].
   Google Scholar